Pd L1

1 article

Scientists in a futuristic lab analyzing bispecific antibody data, representing advancements in lung cancer treatment presented at ASCO.

Pfizer Shares Updated Lung Cancer Bispecifics Data at ASCO

At the ASCO Annual Meeting, updated Phase 2 data for Pfizer's bispecific antibody PF-08634404 demonstrated activity as monotherapy in first-line PD-L1-expressing non-small cell lung cancer.

Yasmin Haddad·May 31, 2026